DBVT News and Press, DBV Technologies S.A. From 05/01/20

DBVT Technologies (NASDAQ: DBVT ) files an offer to sell ordinary shares of an indeterminate amount. More news on: DBV Technologies S.A., Tech stocks news, , Read more ...

Montrouge, France, April 30, 2020 DBV Technologies Reports March 31, 2020 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its cash and cash equivalents and its n...

LMP Automotive Holdings (NASDAQ: LMPX ) +35% . More news on: LMP Automotive Holdings, Inc., AgEagle Aerial Systems, Inc., Soligenix, Inc., Stocks on the move, , Read more ...

Aimmune Therapeutics ( AIMT ) was a stock I followed and invested in and also recommended to my subscribers before the approval. The stock did double over a period of 6 months, however, there were some jittery moments right before Palforzia’s (AR101) approval with unscheduled delays and...

Montrouge, France, April 20, 2020 DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting Shareholders approve all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

On March 16, Aimmune Therapeutics (NASDAQ: AIMT) announced that the first patients in the U.S. had begun treatment with its recently approved immunotherapy for peanut allergies, Palforzia. On the same day, investors learned that the U.S. Food and Drug Administration (FDA) had questions ...

For parents, having a child with peanut allergies come into accidental contact with the protein, via unlabeled foods at a potluck event, birthday party, or school lunch can be devastating. The results range in severity, from minor skin reactions to life-threatening anaphylaxis. It's an...

Introduction At the end of 2019 I wrote an article highlighting the reasons why I felt DBV Technologies (NASDAQ: DBVT ) was substantially undervalued. At the time DBVT was trading for around $9, subsequently climbed to $13.49 by mid-January, and then nosedived to a low of $2.02. The s...

Montrouge, France, April 10, 2020 Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Montrouge, France, March 30, 2020 Ordinary and Extraordinary General Meeting of April 20, 2020 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage b...